SAB Biotherapeutics nabs $14m Series B
Sioux Falls, South Dakota-based SAB Biotherapeutics, a clinical-stage biopharmaceutical company, has raised $14 million in Series B funding.
17 July 2020•1 min read
Sioux Falls, South Dakota-based SAB Biotherapeutics, a clinical-stage biopharmaceutical company, has raised $14 million in Series B funding.